Virucidal treatment of clotting factor concentrates.

Suppr

超能文献

作者信息

Mannucci P M, Colombo M

机构信息

A. Bianchi Bonomi Haemophilia and Thrombosis Centre, University of Milan, Italy.

出版信息

Lancet. 1988 Oct 1;2(8614):782-5. doi: 10.1016/s0140-6736(88)92426-9.

DOI:10.1016/s0140-6736(88)92426-9

PMID:2901620

Abstract

摘要

相似文献

Virucidal treatment of clotting factor concentrates.

Lancet. 1988 Oct 1;2(8614):782-5. doi: 10.1016/s0140-6736(88)92426-9.

Effect of dry-heating of coagulation factor concentrates at 80 degrees C for 72 hours on transmission of non-A, non-B hepatitis. Study Group of the UK Haemophilia Centre Directors on Surveillance of Virus Transmission by Concentrates.

Lancet. 1988 Oct 8;2(8615):814-6.

Serological evidence that dry heating of clotting factor concentrates prevents transmission of non-A, non-B hepatitis.

J Med Virol. 1990 Jan;30(1):50-2. doi: 10.1002/jmv.1890300111.

Therapeutic properties and safety of recombinant factor VIII and factor IX.

Pol Arch Med Wewn. 2009 Jun;119(6):403-9.

From the Centers for Disease Control and Prevention. Hepatitis A among persons with hemophilia who received clotting factor concentrate--United States, September-December 1995.

JAMA. 1996 Feb 14;275(6):427-8.

Addition of hepatitis-B immunoglobulin to clotting factors.

Lancet. 1980 Sep 6;2(8193):537.

Addition of hepatitis-B immunoglobulin to clotting factor.

Lancet. 1980 Sep 6;2(8193):537-8.

[Viral hepatitis in hemophiliac patients treated with commercial concentrates of factors VIII and IX].

Med Clin (Barc). 1985 Apr 6;84(13):516-9.

[Plasma concentrates of factor VIII. Where are we?].

Sangre (Barc). 1989 Feb;34(1):1-3.

Clinical evaluation of viral safety of coagulation factor VIII and IX concentrates.

Vox Sang. 1993;64(4):197-203. doi: 10.1111/j.1423-0410.1993.tb03055.x.

引用本文的文献

Hemophilia and von Willebrand's disease: 1. Diagnosis, comprehensive care and assessment. Association of Hemophilia Clinic Directors of Canada.

CMAJ. 1995 Jul 1;153(1):19-25.

Blood protein derivative viral safety: observations and analysis.

Yale J Biol Med. 1990 Sep-Oct;63(5):361-9.

Viral safety and inhibitor development associated with monoclonal antibody-purified F VIII C.

Ann Hematol. 1991 Sep;63(3):138-41. doi: 10.1007/BF01703244.

Viral contamination of monoclonal antibody preparations: potential problems and possible solutions.

Cytotechnology. 1990 Jul;4(1):3-12. doi: 10.1007/BF00148806.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验